Claes Göran Tropé

Claes Göran Tropé's AcademicInfluence.com Rankings

Claes Göran Tropé

Computer Science

#6723

World Rank

#7084

Historical Rank

Data Science

#134

World Rank

#137

Historical Rank

Computational Linguistics

#1221

World Rank

#1235

Historical Rank

Machine Learning

#2277

World Rank

#2305

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Claes Göran Tropé Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Claes Göran Tropé's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. (2010) (1291)
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. (2000) (1001)
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial (2003) (767)
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma (2001) (591)
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. (2003) (466)
Snail, Slug, and Smad‐interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma (2005) (441)
The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. (1995) (229)
Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis (2000) (201)
A retrospective study of 370 borderline tumors of the ovary treated at the norwegian radium hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities (1993) (188)
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. (2010) (165)
Epithelial ovarian carcinoma (1997) (159)
Diagnosis and treatment of sarcoma of the uterus. A review (2012) (154)
Improved short‐term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals (2006) (151)
Epithelial–Mesenchymal Transition in Ovarian Carcinoma (2012) (151)
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets (2007) (147)
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. (2006) (140)
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. (2005) (138)
Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. (1993) (136)
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer (2015) (131)
A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. (2008) (123)
Clear cell carcinoma of the endometrium: Prognosis and metastatic pattern (1996) (123)
Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer (2003) (123)
Exosome-derived miRNAs and ovarian carcinoma progression. (2014) (119)
Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c‐erbB‐2 in early cervical squamous cell carcinoma: An immunohistochemical study (1996) (113)
miRNA profiling along tumour progression in ovarian carcinoma (2011) (111)
Expression of E-cadherin transcriptional regulators in ovarian carcinoma (2006) (110)
Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma: A randomized multicenter study of sequential cisplatin and 5‐fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A (1996) (110)
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. (2003) (109)
Randomized trial comparing cisplatin with radioactive phosphorus or whole‐abdomen irradiation as adjuvant treatment of Ovarian cancer (1992) (109)
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument (2000) (108)
Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. (1999) (108)
P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. (2000) (107)
Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization. (2000) (106)
Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. (1993) (105)
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells (2012) (104)
DNA copy number changes in malignant ovarian germ cell tumors. (2000) (103)
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort (2011) (101)
Prognostic value of pre‐ and postoperative serum CA 125 levels in ovarian cancer: New aspects and multivariate analysis (1992) (101)
E‐cadherin and α‐, β‐, and γ‐catenin protein expression is up‐regulated in ovarian carcinoma cells in serous effusions (2000) (100)
Carcinoma of the fallopian tube (2000) (99)
Surgery for borderline tumor of the ovary. (2000) (97)
Granulin‐epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma (2004) (95)
HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. (2005) (94)
Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. (2000) (91)
Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis (2002) (90)
DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary (1993) (87)
Borderline ovarian tumours. (2012) (87)
Malignant melanoma of the vulva. Evaluation of prognostic factors with emphasis on DNA ploidy in 75 patients (1995) (84)
The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. (1995) (82)
Management of borderline tumors of the ovary: state of the art. (1998) (81)
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. (2008) (81)
Genetic alterations of the TP53 gene, p53 protein expression and hpv infection in primary cervical carcinomas (1993) (80)
EORTC-GcG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA) (2008) (80)
A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection (2011) (79)
Cancer of the endometrium: value of MR imaging in determining depth of invasion into the myometrium. (1991) (77)
Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. (2000) (77)
The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. (1996) (77)
On the presence within tumours of clones that differ in sensitivity to cytostatic drugs. (2009) (76)
Ovarian Cancer: Diagnostic, Biological and Prognostic Aspects (2014) (76)
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. (2012) (75)
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis. (2003) (74)
Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions (2010) (73)
Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. (2011) (73)
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): Co-expression in metastatic serous ovarian carcinoma (2004) (72)
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma (2007) (71)
Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. (2007) (71)
Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993 (1998) (70)
Proteomic Analysis of Malignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling (2006) (70)
αV- and β1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients (2003) (70)
Long-term outcomes after pelvic radiation for early-stage endometrial cancer. (2013) (68)
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. (2000) (68)
Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. (2001) (68)
Health-related quality of life and occurrence of intestinal side effects after pelvic radiotherapy--evaluation of long-term effects of diagnosis and treatment. (2000) (67)
Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? (2007) (66)
Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. (2003) (66)
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. (2009) (65)
The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. (2009) (65)
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival (2004) (65)
MicroRNAs in Ovarian Cancer. (2015) (64)
Value of Tertiary Cytoreductive Surgery in Epithelial Ovarian Cancer: An International Multicenter Evaluation (2013) (63)
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. (2009) (63)
Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. (2009) (62)
Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer. (2016) (61)
Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. (1999) (61)
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma (2004) (61)
Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. (2001) (60)
Advanced epithelial ovarian cancer (1999) (60)
Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. (1990) (60)
Tamoxifen in the treatment of recurrent ovarian carcinoma. (2000) (59)
MITOGEN-ACTIVATED PROTEIN KINASES (MAPK) AS PREDICTORS OF CLINICAL OUTCOME IN SEROUS OVARIAN CARCINOMA IN EFFUSIONS (2003) (58)
TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas (1997) (57)
An evaluation of prognostic factors in uterine carcinosarcoma. (1997) (57)
Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954‐1993 (1997) (56)
Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. (2001) (56)
Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas (2006) (55)
Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. (1984) (55)
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study (2004) (55)
Surgical management of stage I and II vulvar cancer: The role of the sentinel node biopsy. Review of literature (2001) (55)
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. (2014) (55)
Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. (1992) (53)
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. (2015) (53)
Surgery during chemotherapy and at relapse of ovarian cancer. (1999) (51)
Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009). (2013) (51)
Prospectively detected cancer in familial breast/ovarian cancer screening (1999) (50)
Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. (2001) (50)
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions (2004) (49)
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. (1998) (49)
E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. (2000) (48)
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes (2010) (48)
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. (2011) (48)
Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010). (2014) (48)
Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short‐ and long‐term survivors? (2005) (47)
Early detection of familial ovarian cancer. (1996) (47)
Ets-1 mRNA Expression in Effusions of Serous Ovarian Carcinoma Patients Is a Marker of Poor Outcome (2001) (47)
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. (2004) (46)
Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma – diagnostic and prognostic implications (2004) (46)
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art". (2009) (46)
The clinical and diagnostic role of microRNAs in ovarian carcinoma. (2014) (45)
Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. (2010) (45)
Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA. (1999) (45)
Combined bleomycin and irradiation in preoperative treatment of advanced squamous cell carcinoma of the vulva. (1993) (45)
Prognostic value of flow cytometrical DNA measurements in stage I-II endometrial carcinoma: correlations with steroid receptor concentration, tumor myometrial invasion, and degree of differentiation. (1987) (44)
Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer. (1992) (44)
Clear-cell and papillary serous cancer: treatment options. (2001) (44)
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. (2004) (44)
The Prognostic Value of 14-3-3 Isoforms in Vulvar Squamous Cell Carcinoma Cases: 14-3-3β and ε Are Independent Prognostic Factors for These Tumors (2011) (43)
Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. (2006) (43)
Human papilloma virus has no prognostic significance in cervical carcinoma. (1996) (43)
Low‐molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma (2007) (42)
p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas. (2004) (42)
Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium (2011) (42)
A Systematic Overview of Radiation Therapy Effects in Cervical Cancer (Cervix Uteri) (2003) (42)
The Role of the Tumor Stroma in Ovarian Cancer (2014) (42)
Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. (2007) (41)
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma (2007) (41)
Expression and Clinical Role of Antiapoptotic Proteins of the Bag, Heat Shock, and Bcl-2 Families in Effusions, Primary Tumors, and Solid Metastases in Ovarian Carcinoma (2009) (40)
High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients (2013) (40)
Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival. (2017) (40)
Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975‐94 and treated at the Norwegian Radium Hospital (1998) (39)
Polarographic measurement of pO2 in cervix carcinoma. (1997) (39)
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters. (2009) (38)
Clinical stage I carcinoma of the cervix. Value of MR imaging in determining invasion into the parametrium. (1993) (38)
Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs. (1975) (38)
p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma. (2006) (37)
A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. (2002) (37)
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era". (2015) (37)
A Systematic Overview of Radiation Therapy Effects in Ovarian Cancer (2003) (37)
A phase II study of Cis-platinum for recurrent corpus cancer. (1980) (37)
Age and prognosis in stage Ib squamous cell carcinoma of the uterine cervix. (1983) (36)
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. (2011) (36)
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. (2012) (36)
Arrest of growth of ovarian tumor by tranexamic acid. (1977) (36)
Fertility preservation in gynecologic cancer (2001) (36)
Occult lymph node metastases in early stage vulvar carcinoma patients. (2005) (34)
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma (2015) (34)
TP53 alterations in relation to the cell cycle‐associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus (1999) (34)
Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. (1999) (34)
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma (2005) (33)
The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer. (1999) (33)
Cell clones with different sensitivity to cytostatic drugs in methylcholanthrene-induced mouse sarcomas. (2009) (33)
Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer (2007) (33)
Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis. (2009) (33)
Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. (1993) (33)
On heterogeneity of non-Hodgkin's lymphomas as regards sensitivity to cytostatic drugs. An in vitro study. (1980) (33)
Adenomatous Polyposis Coli (APC) Protein Expression in Primary and Metastatic Serous Ovarian Carcinoma (2002) (33)
AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. (2003) (33)
Flow cytometric DNA analysis of normal and cancerous human endometrium and cytological-histopathological correlations. (1987) (33)
p53 Protein expression in squamous cell carcinoma of the vulva (1999) (32)
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. (2013) (32)
Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications. (2001) (32)
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases (2012) (32)
High-dose medroxyprogesterone acetate for the treatment of advanced ovarian carcinoma. (1982) (31)
Primary surgery for ovarian cancer. (2006) (31)
The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study (2015) (31)
Human Ovarian Tumours Heterotransplanted to “Nude” Mice (1978) (31)
Heterotransplantation of human head and neck tumours into nude mice. (1983) (31)
Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. (2007) (31)
Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva (2013) (30)
No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction in cancer of the uterine cervix: a prospective study of 465 patients. (1995) (30)
Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV? (2012) (30)
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients (2005) (30)
Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer. (2006) (30)
DNA ploidy and expression of p53 and C-erbB-2 in extramammary Paget's disease of the vulva. (1997) (29)
A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing. (1997) (29)
A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice (2009) (29)
Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976–1985 (1992) (29)
Hexamethylmelamine as second‐line therapy in platin‐resistant ovarian cancer (1993) (28)
Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: A prospective study (1994) (28)
Oxygen tension and vascular density in human cervix carcinoma. (1996) (28)
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma. (2015) (28)
The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. (2006) (28)
Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up. (1996) (28)
Symptoms and referral of women with epithelial ovarian tumors (2005) (28)
Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model. (1992) (27)
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. (2013) (27)
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival. (2014) (27)
Some aspects of prophylactic oophorectomy and ovarian carcinoma. (1981) (27)
Caveolin-1 expression in ovarian carcinoma is MDR1 independent. (2002) (27)
Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery. (2011) (27)
HETEROGENEOUS RESPONSE OF DISSEMINATED HUMAN OVARIAN CANCERS TO CYTOSTATICS IN VITRO (1979) (26)
Fatigue and Quality of Life After Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Hereditary Breast-Ovarian Cancer (2009) (26)
Molecular and biological factors in the pathogenesis of ovarian cancer. (1993) (26)
Morbidity associated with "self-rated health" in epithelial ovarian cancer survivors (2009) (26)
The influence of low fat, low lactose diet on diarrhoea during pelvic radiotherapy. (1992) (26)
The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas (2008) (26)
Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. (1998) (25)
CD117 Expression in Fibroblasts-Like Stromal Cells Indicates Unfavorable Clinical Outcomes in Ovarian Carcinoma Patients (2014) (25)
Tumor Spreading to the Contralateral Ovary in Bilateral Ovarian Carcinoma Is a Late Event in Clonal Evolution (2009) (25)
Prospective findings in breast cancer kindreds: annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer (1998) (25)
Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map (2009) (25)
Immunohistochemical analysis of p53 protein in uterine sarcomas. (1998) (25)
A Systematic Overview of Radiation Therapy Effects in Uterine Cancer (Corpus Uteri) (2003) (24)
Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? (1993) (24)
Expression and Clinical Role of Growth Differentiation Factor-15 in Ovarian Carcinoma Effusions (2010) (24)
Expression of seprase in effusions from patients with epithelial ovarian carcinoma. (2007) (24)
Malignant melanoma of the vulva FIGO stage I: Evaluation of prognostic factors in 43 patients with emphasis on DNA ploidy and surgical treatment. (1996) (24)
Melphalan With and Without Doxorubicin in Advanced Ovarian Cancer (1987) (24)
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. (2006) (23)
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. (2013) (23)
Cell cycle perturbations in heterotransplanted squamous‐cell carcinoma of the head and neck after Mitomycin C and Cisplatin treatment (1984) (23)
Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second‐look laparotomy (1993) (23)
Tamoxifen in the Treatment of Recurrent Ovarian Carcinoma (1997) (23)
Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival. (2009) (22)
Bleomycin‐mitomycin C in advanced carcinoma of the cervix: A third look (1982) (22)
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma (2014) (22)
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions. (2005) (22)
Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look. (1992) (22)
Flow cytometric DNA ploidy and S‐phase heterogeneity in advanced ovarian carcinoma (1994) (22)
Pooled Analysis of the Prognostic Relevance of Disseminated Tumor Cells in the Bone Marrow of Patients With Ovarian Cancer (2013) (22)
New determinates of disease progression and outcome in metastatic ovarian carcinoma. (2010) (21)
Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study. (2016) (21)
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival. (2012) (21)
Cyclins D1, D3, E, and A in vulvar carcinoma patients. (2005) (21)
Evaluation of the prognostic significance of nm23/NDP kinase protein expression in cervical carcinoma: an immunohistochemical study. (1996) (21)
A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer. (1990) (21)
CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma. (1992) (21)
Bleomycin alone or combined with mitomycin C in treatment of advanced or recurrent squamous cell carcinoma of the vulva. (1980) (21)
Phase II study of spirogermanium in advanced ovarian malignancy. (1981) (21)
Carcinoma of the ovary, stages I and II. A prospective randomized study of the effects of postoperative chemotherapy and radiotherapy. (1982) (21)
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index (2012) (21)
Involvement of DPP9 in gene fusions in serous ovarian carcinoma (2017) (21)
Array‐CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes (2010) (21)
CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer. (1992) (20)
Ezrin Is Associated with Disease Progression in Ovarian Carcinoma (2016) (20)
Prognosis and management of borderline tumours of the ovary. (1996) (20)
Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977-1991. (2002) (20)
Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. (2012) (20)
Nucleoside transporters are widely expressed in ovarian carcinoma effusions (2012) (20)
Genomic aberrations in borderline ovarian tumors (2010) (19)
HMGA2 expression pattern and TERT mutations in tumors of the vulva (2015) (19)
Coronary Heart Disease Risk Profile in Women Who Underwent Salpingo-Oophorectomy to Prevent Hereditary Breast Ovarian Cancer (2009) (19)
Adriamycin‐Methotrexate Combination Chemotherapy of Advanced Carcinoma of the Cervix: A Third Look (1980) (19)
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: An evidence-based proposal for patient selection. (2011) (19)
Genome profiles of bilateral dysgerminomas, a unilateral gonadoblastoma, and a metastasis from a 46, XY phenotypic female. (2003) (18)
Human papillomavirus infection in Norwegian women with cervical cancer (1994) (18)
Phase II study of Leo 1031 (prednimustine) in advanced ovarian carcinoma. (1979) (18)
Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis (2006) (17)
Hyaluronan Synthase and Hyaluronidase Expression in Serous Ovarian Carcinoma is Related to Anatomic Site and Chemotherapy Exposure (2012) (17)
Flow cytometric DNA measurements in squamous cell carcinoma of the vulva: an important prognostic method (1991) (17)
Primary Invaswe Squamous Cell Carcinoma of the Vagina (1989) (17)
VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. (2014) (17)
Intraperitoneal treatment and dose-intense therapy in ovarian cancer. (1999) (17)
Sex Hormone-Binding Globulin (SHBG) Expression in Ovarian Carcinomas and Its Clinicopathological Associations (2013) (17)
The EPH Receptor Bs (EPHBs) Promoters are Unmethylated in Colon and Ovarian Cancers (2007) (16)
Current status of chemotherapy in gynecologic cancer. (1997) (16)
Carcinoma of the Fallopian Tube: Clinicopathologic Study of 151 Patients Treated at the Norwegian Radium Hospital (2001) (16)
Radiation therapy and surgery in the treatment of regional lymph nodes in squamous cell carcinoma of the vulva. (1984) (16)
Expression and clinical role of long non-coding RNA in high-grade serous carcinoma. (2018) (16)
Mass screening for cervical cancer in Norway: evaluation of the pilot project (1995) (16)
Distribution of intraperitoneally injected microspheres labeled with the alpha-emitter astatine (211At) compared with phosphorus (32P) and yttrium (90Y) colloids in mice. (1992) (16)
Corrigendum to “Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis” [Gynecol. Oncol. 89 (2003) 140–147] (2004) (16)
Genomic profile of ovarian carcinomas (2014) (16)
Prognosis of adenocarcinoma of the uterine cervix. (1979) (16)
Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva (2016) (16)
The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck. (1988) (16)
Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals (2005) (15)
Prospective malignancy grading and flow cytometry DNA distribution in biopsy specimens from invasive squamous cell carcinoma of the uterine cervix. (1987) (15)
Histologic pattern and growth in two human testis cancers before and after transplantation to nude mice (1982) (15)
DNA ploidy in epithelial ovarian cancer: a new independent prognostic factor? (1994) (15)
The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas (2018) (15)
Consistent numerical chromosome aberrations in thecofibromas of the ovary (2008) (15)
Epidemiology, etiology, screening, prevention, and diagnosis in female genital cancer (1991) (15)
Relapse of endometrial carcinoma related to steroid receptor concentration, staging, histologic grading and myometrial invasion. (1986) (15)
Inherited breast carcinoma--prospective findings in 1,194 women at risk. (1996) (15)
Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival. (2006) (15)
Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variables. (2004) (14)
Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression (2017) (14)
Invasive squamous cell carcinoma of the uterine cervix. VIII. Survival and malignancy grading in patients treated by irradiation in Lund 1969-1970. (1985) (14)
Clinical Stage I Carcinoma of the Cervix (1993) (14)
Prognostic factors in ovarian cancer. (1998) (14)
Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary (1992) (14)
HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival. (2016) (14)
Decreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma. (2016) (14)
Radical radiotherapy versus brachytherapy plus surgery in carcinoma of the cervix 2A and 2B--long-term results from a randomized study 1968-1980. (1996) (13)
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma (2012) (13)
Prognostic value of steroid receptor concentration and flow cytometrical DNA measurements in stage I-II endometrial carcinoma. (1989) (13)
Low Frequency of ESRRA–C11orf20 Fusion Gene in Ovarian Carcinomas (2014) (13)
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women’s Cancers (2015) (13)
Primary Tumor Vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact (2013) (13)
Detection of genital papillomavirus types by polymerase chain reaction using common primers (1991) (13)
Plasma steroid hormones, cytosol receptors, and thymidine incorporation rate in endometrial carcinoma. (1984) (13)
DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium (2012) (13)
Surgery during chemotherapy and at relapse of ovarian cancer (1999) (13)
Histopathological characteristics predictive for growth of squamous cell carcinomas of the head and neck heterotransplanted to nude mice. (1986) (12)
Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion. (2013) (12)
Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells. (1997) (12)
Netrin‐4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors (2011) (12)
Colony-forming ability of human ovarian carcinomas in the Courtenay soft agar assay. (1989) (12)
A new approach to treatment of early-stage cervical carcinoma: entire laparoscopic abdominal radical hysterectomy with bilateral pelvic lymphadenectomy without vaginal cuff closure--case reports. (2006) (11)
A Serous Ovarian Cystadenocarcinoma Metastatic to Both Eyes (1987) (11)
Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective (2012) (11)
Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. (2011) (11)
In vitro responsiveness of human gastric carcinoma to pentagastrin. (1977) (11)
Management of malignant ovarian immature teratoma. Role of adriamycin (1990) (11)
A 16‐Year‐Old Girl With Invasive Carcinoma Of The Vulva (1990) (11)
A prospective and randomized trial comparison of melphalan VS adriamycin-melphalan in advanced ovarian carcinoma by the Swedish Cooperative Ovarian Cancer Study Group (SCOCSG) (1981) (11)
Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis (2007) (11)
Antineoplastic-drug effect evaluated with a new X-ray stereophotographic measurement of the tumour volume. (1978) (10)
Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer. (1998) (10)
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. (2016) (10)
Endometrial cancer: The management of high-risk disease (2004) (10)
Randomized trial on adjuvant carboplatin versus no treatment in stage I high risk ovarian cancer by th Nordic Ovarian Cancer Study Group (NOCOVA) (1997) (10)
SLNB and the importance of micrometastases in vulvar squamous cell carcinoma. (2008) (10)
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation (2010) (10)
Mitochondrial DNA Deficiency in Ovarian Cancer Cells and Cancer Stem Cell-like Properties. (2015) (10)
Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients. (2000) (10)
Quantitation and localization of cellular retionol‐binding protein in squamous‐cell carcinomas of the cervix uteri and of the oral cavity (1988) (10)
Expression of CDK1Tyr15, pCDK1Thr161, Cyclin B1 (Total) and pCyclin B1Ser126 in Vulvar Squamous Cell Carcinoma and Their Relations with Clinicopatological Features and Prognosis (2015) (10)
WNT-inducible signaling pathway protein 3, WISP-3, is mutated in microsatellite unstable gastrointestinal carcinomas but not in endometrial carcinomas. (2003) (10)
Radical vulvectomy with warm-knife and open-wound techniques in vulvar malignancies. (1984) (10)
DNA Ploidy Heterogeneity in Endometrial Carcinoma: Comparison Between Curettage and Hysterectomy Specimens (2010) (10)
Expression of zinc finger E-box-binding homeobox factor 1 in epithelial ovarian cancer: A clinicopathological analysis of 238 patients (2015) (10)
Tranexamic Acid for the Treatment of Advanced Ovarian Carcinoma (1983) (10)
TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma. (2017) (9)
Prospective malignancy grading, flow cytometry DNA-measurements and adjuvant chemotherapy for invasive squamous cell carcinoma of the uterine cervix. (1993) (9)
Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second-look laparotomy. (1993) (9)
Cancer epithelial de l'ovaire (stades evolues): Conference de consensus (1998) (2000) (9)
Vaginal smear history in patients with invasive cervical carcinoma. (1979) (9)
Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas—an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications (2009) (9)
Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001. (2007) (9)
A phase II study of 4'-EPI-doxorubicin in advanced ovarian carcinoma (1982) (9)
Giant Condyloma Acuminatum with Focal Malignant Degeneration (1982) (9)
Intergroup collaboration in ovarian cancer: a giant step forward (1999) (9)
BASAL CELL CARCINOMA OF THE VULVA (1985) (9)
Survival after radiation therapy for early-stage endometrial carcinoma: The Oslo study revisited after up to 43 years of follow-up. (2012) (9)
Prevalence and Determinants of Metabolic Syndrome and Elevated Framingham Risk Score in Epithelial Ovarian Cancer Survivors: A Controlled Observational Study (2008) (9)
[Villous glandular adenocarcinoma of the uterine cervix. A subtype with favourable prognosis?]. (1993) (8)
Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group. (1996) (8)
Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium. (2012) (8)
An in vitro study of the effect of cytostatic drugs on DNA synthesis in methylcholanthrene induced mouse sarcomas and in rat Walker 256 tumours. (2009) (8)
Intergroup collaboration in ovarian cancer: a giant step forward. (1999) (8)
Paclitaxel in untreated FIGO stage III suboptimally resected ovarian cancer. (1997) (8)
Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma. (1998) (8)
Gynecologic malignancy and surgery: from quantity to quality of life (1992) (8)
Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum‐sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry‐based study (2018) (7)
Intra-arterial mitomycin C and intravenous bleomycin as induction chemotherapy in advanced head and neck cancer--a phase II study. (1986) (7)
A novel truncated form of HMGA2 in tumors of the ovaries. (2016) (7)
Transcatheter Intraarterial Management of Gynecologic Tumors (1985) (7)
Critical soft tissues of the female pelvis: serial MR imaging before, during, and after radiation therapy. (1997) (7)
Papillary serous carcinoma of the ovary: an ultrastructural and immunohistochemical study. (2004) (7)
Beta 2-microglobulin in squamous cell carcinomas of the head and neck and in tumours heterotransplanted into nude athymic mice. (1984) (7)
Histological grading and treatment failures in carcinoma of the uterine body. (1980) (7)
A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas (2004) (7)
Ovarian carcinoma cells in effusions show increased S‐phase fraction compared to corresponding primary tumors (2008) (6)
Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies (1992) (6)
Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer (2003) (6)
Normobaric oxygen treatment during radiotherapy for carcinoma of the uterine cervix. Results from a prospective controlled randomized trial. (1999) (6)
Epithelial–mesenchymal transition markers in malignant ovarian germ cell tumors (2017) (6)
[A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer]. (1990) (6)
Gestational trophoblastic tumors in Norway, 1968-1997: patient characteristics, treatment, and prognosis. (2002) (6)
[Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. (2000) (6)
Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma (2018) (6)
Changes in histology and cell kinetics during the growth course of xenografted squamous cell carcinoma. (1988) (6)
Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous cell carcinoma of the cervix. (1999) (6)
Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases. (2013) (6)
A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. (1995) (6)
Is the watch and wait approach adequate after comprehensive surgical staging in invasive stage I epithelial ovarian cancer? The Norwegian Radium Hospital experience. (2008) (6)
Stage I squamous cell carcinoma of the vulva. (1984) (6)
Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma. (2017) (6)
Papillomaviruses, p53, and cervical cancer. (1992) (5)
Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro (2018) (5)
Doxorubicin-cisplatin combination chemotherapy for recurrent carcinoma of the cervix. (1986) (5)
Lymphoid cell distribution as prognostic factor in carcinoma of the uterine cervix (1992) (5)
Unsettled questions regarding ovarian cancer (1992) (5)
Controversies in surgical management of advanced ovarian cancer (stage III-IV). (2000) (5)
β-microglobulin: A tumor marker of gynecologic cancer (1980) (5)
Lactate dehydrogenase isoenzyme 1 (LDH-1) in athymic mice with xenografts of a human testicular germ cell tumor (1982) (5)
Long‐term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin‐based chemotherapy for malignant ovarian germ cell tumor (2018) (5)
Aldehyde dehydrogenase-1 predicts favorable prognosis in patients with vulvar squamous cell carcinoma. (2014) (5)
The effect of continuous bleomycin infusion on the growth and cell kinetics of heterotransplanted squamous cell carcinoma of the head and neck. (1987) (5)
The recovery pattern of patients with vulvar melanoma treated by combined surgery and radiation therapy. (1982) (5)
Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation. (2007) (4)
Influence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endometrial cancer (1994) (4)
Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? (2004) (4)
Improved 8-Year Survival for Patients With Stage IIIC Ovarian Cancer Operated on at Teaching Hospitals: Population-Based Study in Norway 2002 (2012) (4)
Flow Cytometry in Invasive Endometrial Carcinoma (1991) (4)
P-gp expression as a possible marker for response to cisplatin/epirubicin as first line treatment in advanced ovarian cancer: 135 (1994) (4)
[Primary treatment of ovarian cancer]. (2005) (4)
Metastasis of a cultured human bladder carcinoma cell line transplanted into nude athymic mice. (1982) (4)
Bilateral ovarian carcinomas differ in the expression of metastasis-related genes (2016) (4)
CO2 laser for the treatment of invasive vulvar and vaginal cancer. (1983) (4)
Correlation between estradiol-17 beta and progesterone cytosol receptor concentration, histologic differentiation and 3H-thymidine incorporation in endometrial carcinoma. (1982) (3)
Human malignant melanoma heterotransplanted to nude mice. (1981) (3)
Heterogeneity in in vitro response to progesterone and melphalan of mammary tumours induced in the rat by 7,12-DMBA. (2009) (3)
Expression of p15INK4b and p57KIP2 and Relationship with Clinicopathological Features and Prognosis in Patients with Vulvar Squamous Cell Carcinoma (2013) (3)
An international perspective on surgical health care and education. (2007) (3)
Prognostic factors in platinum-resistant ovarian carcinoma treated with ifosfamide-etoposide. (2000) (3)
Flow cytometric measurement of cellular FLICE‐inhibitory protein (c‐FLIP) in ovarian carcinoma effusions (2011) (3)
Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival. (2016) (3)
Effect of 2-mercaptoethanol on the mixed leukocyte reaction in man. Probable effect on blastogenic factor stabilization. (2009) (3)
The problem of skipped generation and subclinical disease in familial breast‐ovarian cancer (1997) (3)
A randomised study of cisplatin versus thiotepa as induction chemotherapy in advanced ovarian carcinoma. (1994) (3)
Cellular DNA content: the most important prognostic factor in patients with borderline tumors of the ovary. Can it prevent overtreatment? (1995) (2)
[Paclitaxel should be included in standard therapy of ovarian carcinoma]. (2003) (2)
Changes in Cell Cycle Phase Distribution during Growth of Heterotransplanted Squamous Cell Carcinoma (1987) (2)
TP53 mutation and HPV-infection in primary cervical carcinomas (1992) (2)
High-resolution Image Analysis - A Better Method for Predicting Prognosis in Early Ovarian Cancer (2000) (2)
Recurrent fusion transcripts in squamous cell carcinomas of the vulva (2017) (2)
Expression of 14‐3‐3 sigma and eta proteins is unrelated to survival in metastatic high‐grade serous carcinoma (2018) (2)
[Surgery and sentinel node examination in early vulvar cancer]. (2001) (2)
Heterotransplantation of human malignant endometrial tumors into nude mice. (1988) (2)
Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases (2006) (2)
A PHASE II STUDY OF 5-FU/ CIS IN RECURRENT CERVICAL CANCER (1990) (2)
Effect of tranexamic acid on progress of experimental tumours and on DNA-synthesis (1980) (2)
Carcinoma of the ovary in stage III. Effects of postoperative chemotherapy, radiation therapy and repeat laparotomy. (1982) (2)
Endometrial and ovarian malignancies: epidemiology, etiology and prognostic factors (1992) (2)
The role of surgery in the second relapse of epithelial ovarian cancer. Selection criteria, morbidity and survival outcome. (2011) (2)
In vitro effects of prolactin and hydrocortisone on 7,12-DMBA-induced mammary tumour and virus-induced sarcoma in the rat. (2009) (2)
[Controversies in surgical treatment of advanced ovarian cancer]. (2000) (2)
TGFβ splicing and canonical pathway activation in high-grade serous carcinoma (2017) (2)
Computed Tomography in Advanced Carcinoma of the Uterine Cervix (1984) (2)
Adjuvant Therapy for Early-Stage Epithelial Ovarian Cancer (1997) (2)
Modern prognostic factors in cervical cancer with special attention to early disease (2001) (2)
Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up. (1998) (2)
Cellular DNA Content as a New Prognostic Tool in Patients with Borderline Tumors of the Ovary. A Second Look (1993) (2)
Effect of estradiol on tumor growth, cell kinetics and p53 oncoprotein expression in human endometrial adenocarcinoma heterotransplanted into nude mice. (1993) (2)
High-dose metoclopramide in the treatment of cis-platinum induced emesis. A dose-finding study. (1985) (2)
Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer. (2001) (2)
Adjuvant Treatment for Early-Stage Epithelial Ovarian Cancer (2004) (1)
Comparison of estrogen receptor enzyme immunoassay and a radioligand binding assay (isoelectric focusing) in adenocarcinoma of the uterine body. (1987) (1)
Abstract 5170: The autotaxin-lysophosphatidic acid signaling pathways in ovarian carcinoma (2015) (1)
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells (2012) (1)
Borderlinetumorer i ovariene (2000) (1)
[Early stage ovarian carcinoma--diagnosis and treatment]. (2000) (1)
DNA flow cytometry as a new prognostic factor in ovarian malignancies (1992) (1)
What Is the Best Treatment Model for Gynecologic Cancers? Does Centralization Help? (2014) (1)
Comparison of HPV detection in parallel biopsies and cervical scrapes by PCR (1992) (1)
Genomic profile of ovarian carcinomas (2014) (1)
Meningioma-like endometrial stromal nodule with a stromal-derived foam cell component (2006) (1)
Abstract 517: LncRNA expression at the different site of high-grades serous carcinoma (2018) (1)
[Molecular diagnostic techniques in gynaecologic cancer]. (2005) (1)
Improved survival for ovarian cancer patients stage IIIC treated at the Norwegian Radium Hospital between 1984 - 2001 (2007) (1)
Chemotherapy of Metastatic Carcinoma of the Breast (1977) (1)
Selected abstracts submitted to the Third International Symposium on Hereditary Breast and Ovarian Cancer (2009) (1)
Selective elimination in vitro of sensitive cell clones in methylcholanthrene induced sarcoma by vinblastine sulphate. (2009) (1)
Endometriehyperplasi - Diagnose og behandling (1999) (1)
Laparoscopic radical hysterectomy: Technical gimmick or surgical advance? (1993) (1)
Gestational trophoblastic tumors: cytostatic treatment response evaluated from hCG modelling (1992) (1)
[Endometrial hyperplasia--diagnosis and treatment]. (1999) (1)
A phase II study of toremifene in carcinoma corporis uteri. Preliminary communication. (1990) (1)
Influence of "nuclear" estrogen receptor content on prognosis of early stage carcinoma of the uterine body. A short-time follow-up. (1990) (1)
Primary Tumor Vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact (2013) (1)
O521 SURVIVAL AFTER POSTOPERATIVE RADIOTHERAPY FOR EARLY STAGE ENDOMETRIAL CARCINOMA: THE OSLO STUDY REVISITED AFTER UP TO 43 YEARS OF FOLLOW‐UP (2012) (1)
[DNA ploidy in epithelial ovarian cancer--an independent prognostic factor]. (2000) (1)
A Phase II Study of Combined Adriamycin, L-PAM, and Methotrexate with Citrovorum Factor Rescue in Advanced Ovarian Carcinomas (1977) (1)
Heterotransplantation of human endometrial tumours to nude mice (1987) (0)
An in vitro study of cytostatic drug effect on the dna synthesis in methylcholanthrene induced mouse sarcomas. Correlation between in vitro results and the response in vivo. (2009) (0)
Impact from primary and recurrent treatment on survival of FIGO IIIc epithelial ovarian cancer patients. (2014) (0)
Per Kolstad (1925–1991) (1992) (0)
' s response to reviews Title : The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas (2008) (0)
Usefulness of flow cytometric DNA measurements in genital and breast cancers. (1989) (0)
[Mass screening against endometrial cancer?]. (2002) (0)
PP-4-7 Early diagnosis of inherited breast cancer (1996) (0)
386 Unique MiRNA Signature and Oncogenic Potential of Effusion Fluid-derived Exosomes From Ovarian Carcinoma Patients (2012) (0)
Prevalence of mammary carcinoma in patients with gynaecologic cancer. (1987) (0)
Estrogen receptor content in nuclear pellet from adenocarcinoma corporis uteri biopsies. (1989) (0)
DNA Copy Number Changes in Malignant Ovarian Germ Cell Tumors 1 (2000) (0)
Quality of surgery in advanced ovarian cancer: audit of original surgery reports of 442 patients from the EORTC-GCG/NCIC-CTG Neoadjuvant Trial (2008) (0)
Heterotransplantation of two human tumours in athymic mice and asplenic-athymic mice. (2009) (0)
The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas (2018) (0)
Malignant germ cell ovarian cancer (MGCOC) in the Cancer Registry of Norway (CRN): A long-term follow-up study of presentation, survival, and second cancers. (2013) (0)
UTERINE AND OVARIAN CARCINOSARCOMA (CS). THE EXPERIENCE FROM THE NORWEGIAN RADIUM HOSPITAL DURING A 20 YEAR PERIOD (2003) (0)
Cisplatin and 5-Fluorouracil Have a Synergistic Effect on Heterotransplanted Squamous Cell Carcinoma1 (1987) (0)
[Hormone replacement therapy and cancer]. (1997) (0)
Erratum: "Expression of seprase in effusions from patients with epithelial ovarian carcinoma" (Chinese Medical Journal (2007) vol. 120 (8) (663-668)) (2008) (0)
[Ovarian cancer screening of high risk groups]. (2000) (0)
1184 The prognostic significance of NM23, Cathepsin-D, EGFR and C-ERBB-2 in cervical cancer (1995) (0)
Author's response to reviews Title: The Hypoxic Microenvironment Upgrades Stem-like properties of Ovarian Cancer Cells Authors: (2012) (0)
Author ' s response to reviews Title : The expression of aldehyde dehydrogenase 1 ( ALDH 1 ) in ovarian carcinomas and its clinicopathological associations : a retrospective study (2015) (0)
0-43. Early diagnosis of inherited breast cancer (1997) (0)
The close follow-up of immunosuppressed renal recipient women through colposcopy, cervical biopsy and FCM DNA content analysis. (1991) (0)
Changes in tumor morphology in one human endometrial carcinosarcoma heterotransplanted into nude mice. (1989) (0)
An in vitro study of the effect of cytostatic drugs on the DNA synthesis in experimental tumours, selection of cell clones during growth, transplantation, and metastasis (1974) (0)
Abstract 2068: Profile, target genes and regulation of microRNAs in ovarian carcinoma tumor progression (2010) (0)
Clear cell carcinoma of the endometrium: Prognosis, metastatic pattern and treatment modalities. A study of 181 patients (1995) (0)
Early diagnosis of familial breast cancer (1993) (0)
Primary cytoreductive surgery or neoadjuvant chemotherapy: A retrospective analysis of 214 patients with stage IIIc and IV ovarian, tubal and peritoneal cancer from the Norwegian Radium Hospital (2007) (0)
DNA PLOIDY IN 123 CASES OF ADULT GRANULOSA CELL TUMORS OF THE OVARY (2004) (0)
Prognostic factors in malignant ovarian germ cell tumors: The SEER experience 1978-2010. (2014) (0)
[CO2 laser in surgical treatment of vulvar and vaginal cancer]. (1985) (0)
Quality of histopathology in advanced ovarian cancer: audit of original pathology reports of 466 patients from the EORTC-GCG/NCIC-CTG Neoadjuvant Trial (2008) (0)
[Screening for ovarian cancer]. (2000) (0)
Treatment of recurrent cervical cancer with adriamycin and methotrexate in combination (1980) (0)
High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients (2013) (0)
PHASE II TRIAL OF CISPLATIN, IFOSFAMIDE AND 5-FU WITH LEUCOVORIN AS NEO-ADJUVANT TREATMENT BEFORE SURGERY IN STAGE IB2 - IIB CERVICAL CANCER (2003) (0)
Fertility preservation in gynecologic cancer. (2001) (0)
[A new prognostic instrument. Histopathological multi-factor analysis of invasive squamous cell carcinoma of the cervix uteri]. (1985) (0)
Survival After Secondary Cytoreductive Surgery and Chemotherapy Compared With Chemotherapy Alone for First Recurrence in Patients With Platinum-Sensitive Epithelial Ovarian Cancer and No Residuals After Primary Treatment. A Registry-Based Study (2018) (0)
Supplementary Information for HOTAIR AND ITS SURROGATE DNA METHYLATION SIGNATURE INDICATE CARBOPLATIN RESISTANCE IN OVARIAN CANCER (2015) (0)
Management of cervical carcinoma stage IV: Comment (2010) (0)
[Preoperative identification of malignancy among women with a pelvic mass]. (1995) (0)
[Tissue damage after extravasal deposition of doxorubicin]. (1982) (0)
Ovarialkarsinom i tidlig stadium - Diagnostikk og behandling (2000) (0)
[Borderline tumors of the ovary]. (2000) (0)
0008 IMPROVED SHORT-TERM SURVIVAL FOR ADVANCED OVARIAN, TUBAR AND PERITONEAL CANCER PATIENTS OPERATED BY SPECIALIZED GYNECOLOGISTS (2005) (0)
[DNA examinations in gynecological cancer and breast cancer]. (1991) (0)
Adriamycin combined with melphalan versus melphalan in a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group (SCOCSG) (1980) (0)
beta 2-Microglobulin: a tumor marker of gynecologic cancer. (1980) (0)
Abstract 2031: The noncanonical pathways of transforming growth factor β in ovarian carcinoma (2018) (0)
Abstract 5166: THE WNT SIGNALING PATHWAY IN THE OVARIAN CARCINOMA (2015) (0)
Danazol treatment in DMBA induced rat mammary carcinoma (1979) (0)
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma (2015) (0)
Cyst rupture during surgery (2001) (0)
Abstract 3197: Exosome secretion in ovarian carcinoma (2015) (0)
An in vitro study of cytostatic drug effect on the drug effect on the DNA synthesis in methylcholanthrene induced mouse sarcomas. Correlation between in vitro results and the response in vivo. (1974) (0)
[A year's experience in an abortion consultation clinic connected with the Landskrona child care center]. (1951) (0)
The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study (2015) (0)
Use of tissue culture and 'nude' mice in predictive testing of drug sensitivity in human ovarian cancer. Correlation in vitro and in vivo (1980) (0)
0599: A Controlled Study of Somatic Morbidity, Mental Distress, Fatigue, and Quality of Life in Short and Long-Term Epithelial Ovarian Cancer Survivors (2006) (0)
Abstract 3052: Ovarian carcinoma derived exosomes: miRNA signatures and role in cancer progression . (2013) (0)
Gene may predict aggressive ovarian cancer (2005) (0)
Evaluation of the prognostic significance of DNA ploidy and S-phase fraction in cancer of the uterine cervix (2001) (0)
A STUDY OF PROGNOSTIC PARAMETERS PREDICTING LONG-TERM SURVIVAL IN STAGE III EPITHELIAL OVARIAN CANCER (2004) (0)
156 Profile, target genes and regulation of microRNAs in ovarian carcinoma tumour progression (2010) (0)
Abstract 5182: Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma (2018) (0)
[Laparoscopic surgery in endometrial carcinoma]. (2002) (0)
Chemotherapy of metastatic carcinoma of the breast. A 4-drug regimen. (1977) (0)
[Bleomycin combined with mitomycin C in recurrent cervix cancer]. (1982) (0)
Management of early epithelial ovarian cancer (2004) (0)
[Treatment of recurrent cervical cancer with doxorubicin in combination with methotrexate]. (1980) (0)
505 A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced ovarian carcinoma (AOC) (1995) (0)
Improving the quality of anti-emetic therapy. (1994) (0)
Involvement of DPP9 in gene fusions in serous ovarian carcinoma (2017) (0)
Intraperitoneal antineoplastic agents in the management of ovarian cancer. (1991) (0)
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma (2006) (0)
Chemotherapy with ifosfamide and etoposide in ovarian carcinoma with true platinum-resistance (1995) (0)
A phase II study of prednimustine (LEO 1031) in ovarian carcinoma not responding to conventional and irradiation therapy (1979) (0)
[From wonder to alarm--the Tidsskriftet, the Nobel Prize and the HPV vaccine]. (2009) (0)
The treatment of recurrent cervical cancer (2010) (0)
Influence of estrogen receptors on tumor growth in adenocarcinoma corporis uteri heterotransplanted to nude mice (1987) (0)
[Staging and differentiated grading are the factors influencing mortality in ovarian cancer]. (1984) (0)
[A phase II study of prednimustine in advanced ovarian cancer]. (1980) (0)
Can it prevent overtreatment ? (0)
Framingham risk score after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer: A controlled observational study. (2009) (0)
Short-term survival of ovarian cancer patients waiting more than six weeks after surgery before chemotherapy is given. (2006) (0)
Effect of low-lactose/low-fat diet during pelvic radiotherapy (1991) (0)
Histopathologic multifactorial analysis of invasive squamous cell carcinoma of the uterine cervix (1985) (0)
0171: Enhanced Expression of Metallinoproteases (Mmp-2) in Primary Serous Borderline Ovarian Tumors with Implants Compared to Ovaries Without Implants (2006) (0)
Author's response to reviews Title: Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes Authors: (2010) (0)
Improving quality of antiemetic therapy (AT) (1993) (0)
Tissue damage consequent upon extravasal deposition of doxorubicin (1982) (0)
TP53 MUTATIONS IN ADVANCED OVARIAN CARCINOMA (AOC); RELATION TO SURVIVAL (2003) (0)
[Ovarian cancer and borderline tumors]. (1998) (0)
Oxygentension andvascular density inhumancervix carcinoma (1996) (0)
Histochemical study with an oestrogen receptor related protein in endometrial carcinoma and its correlation with biochemical oestrogen receptor status (1990) (0)
TP53 MUTATIONS IN EARLY STAGE EPITHELIAL OVARIAN CARCINOMA (EOC); RELATION TO LONG TERM SURVIVAL (2003) (0)
Ovarian cancer — Are we making progress? (1997) (0)
[Screening for cancer]. (1999) (0)
Author ' s response to reviews Title : Gross genomic alterations and gene expression profiles of high-grade serous carcinoma of the ovary with and without BRCA 1 inactivation (2010) (0)
Author ' s response to reviews Title : Gross genomic alterations and gene expression profiles of high-grade serous carcinoma of the ovary with and without BRCA 1 inactivation (2010) (0)
Sexual activity and functioning in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. (2010) (0)
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Claes Göran Tropé?

Claes Göran Tropé is affiliated with the following schools:

Claes Göran Tropé's Academic­Influence.com Rankings

Why Is Claes Göran Tropé Influential?

Claes Göran Tropé's Published Works

Published Works

What Schools Are Affiliated With Claes Göran Tropé?

Claes Göran Tropé's AcademicInfluence.com Rankings